Literature DB >> 34661895

Pathogenesis and Host Immune Response in Leprosy.

Hadida Yasmin1, Praveen Mathews Varghese2,3, Sanjib Bhakta4, Uday Kishore2.   

Abstract

Leprosy is an ancient insidious disease caused by Mycobacterium leprae, where the skin and peripheral nerves undergo chronic granulomatous infections, leading to sensory and motor impairment with characteristic deformities. Susceptibility to leprosy and its disease state are determined by the manifestation of innate immune resistance mediated by cells of monocyte lineage. Due to insufficient innate resistance, granulomatous infection is established, influencing the specific cellular immunity. The clinical presentation of leprosy ranges between two stable polar forms (tuberculoid to lepromatous) and three unstable borderline forms. The tuberculoid form involves Th1 response, characterized by a well demarcated granuloma, infiltrated by CD4+ T lymphocytes, containing epitheloid and multinucleated giant cells. In the lepromatous leprosy, there is no characteristic granuloma but only unstructured accumulation of ineffective macrophages containing engulfed pathogens. Th1 response, characterised by IFN-γ and IL-2 production, activates macrophages in order to kill intracellular pathogens. Conversely, a Th2 response, characterized by the production of IL-4, IL-5 and IL-10, helps in antibody production and consequently downregulates the cell-mediated immunity induced by the Th1 response. M. lepare has a long generation time and its inability to grow in culture under laboratory conditions makes its study challenging. The nine-banded armadillo still remains the best clinical and immunological model to study host-pathogen interaction in leprosy. In this chapter, we present cellular morphology and the genomic uniqueness of M. leprae, and how the pathogen shows tropism for Schwann cells, macrophages and dendritic cells.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Foamy macrophages; Giant cells; Granuloma; Lepromatous leprosy; Mycobacterium laprae; Schwann cells; Tuberculoid leprosy

Mesh:

Year:  2021        PMID: 34661895     DOI: 10.1007/978-3-030-67452-6_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  83 in total

Review 1.  Skin test development in leprosy: progress with first-generation skin test antigens, and an approach to the second generation.

Authors:  P J Brennan
Journal:  Lepr Rev       Date:  2000-12       Impact factor: 0.537

Review 2.  The role of experience in avian navigation and homing.

Authors:  R Wiltschko
Journal:  EXS       Date:  1991

3.  Cementless fixation of hip prostheses in dogs.

Authors:  P Massin; O Badelon; R Cavagna; L Bocquet; J Duparc
Journal:  Int Orthop       Date:  1991       Impact factor: 3.075

4.  How should bromodeoxyuridine labeling be counted?

Authors:  J J Going
Journal:  Am J Clin Pathol       Date:  1991-09       Impact factor: 2.493

5.  Has the basic metabolic defect of cystinosis been discovered?

Authors:  J A Schneider
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

6.  [Recognition of words and their meaning].

Authors:  W Krzemińska
Journal:  Pieleg Polozna       Date:  1979

7.  Indole-2-carboxylic acid: a competitive antagonist of potentiation by glycine at the NMDA receptor.

Authors:  J E Huettner
Journal:  Science       Date:  1989-03-24       Impact factor: 47.728

8.  What has happened to the thermometer?

Authors:  J A Malloch
Journal:  N Z Med J       Date:  1979-04-25

9.  Mapping of the plasmid (pLQ3) from Achromobacter and cloning of its cephalosporinase gene in Escherichia coli.

Authors:  R Levesque; P H Roy
Journal:  Gene       Date:  1982-04       Impact factor: 3.688

10.  Cystoid macular edema following corneal-relaxing incisions.

Authors:  J Carter; B A Barron; M B McDonald
Journal:  Arch Ophthalmol       Date:  1987-01
View more
  1 in total

Review 1.  A review of nutrition in neuropathic pain of leprosy.

Authors:  Michael Klowak; Andrea K Boggild
Journal:  Ther Adv Infect Dis       Date:  2022-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.